Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Chinese Population Aged 40 Years and Older
NCT ID: NCT06851832
Last Updated: 2025-03-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
960 participants
INTERVENTIONAL
2025-02-16
2028-09-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals
NCT06932523
Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above
NCT05856084
Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above
NCT05636436
A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 40 Years and Older
NCT07311148
Long-term Efficacy of Recombinant Zoster Vaccine (CHO Cell) Study
NCT07293065
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Recombinant zoster Vaccine (CHO cell) (low adjuvant)
It is used for vaccination of experimental vaccine group A subjects in phase I and II clinical trials
Recombinant zoster vaccine(CHO cell)(low adjuvant)
The dosage for each administration is 0.5 mL, containing 50 μg of gE, 0.25 mL of MF59, and 50 μg of CpG1018, administered intramuscularly into the deltoid muscle. A total of two doses will be given, with the second dose administered 30 days after the first dose.
Recombinant zoster Vaccine (CHO cell)
It is used for vaccination of experimental vaccine group B subjects of phase I clinical trial , experimental vaccine group B1 and B2 subjects of phase II clinical trial
Recombinant Zoster Vaccine (CHO cell)
The dosage for each administration is 0.5 mL, containing 50 μg of gE, 0.25 mL of MF59, and 100 μg of CpG1018, administered intramuscularly into the deltoid muscle.
Vaccination Schedule 1: A total of two doses will be given, with the second dose administered 30 days after the first dose.
Vaccination Schedule 2: A total of two doses will be given, with the second dose administered 60 days after the first dose \[only applicable to the Phase II Experimental Vaccine Group B2\].
Zoster Vaccine, Live
It is used for vaccination of positive control group A1 and A2 subjects in phase Ⅱ clinical trial
Zoster Vaccine, Live
The dosage for each administration is 0.5 mL, containing not less than 4.3 lg PFU of varicella-zoster live virus, administered subcutaneously at the attachment site of the lower edge of the deltoid muscle on the outer side of the upper arm.
A total of one dose will be given. To maintain blinding, the positive control group A1 will receive a placebo on Day 0 and the Zoster Vaccine, Live on Day 30. The positive control group A2 will receive a placebo on Day 0 and the Zoster Vaccine, Live on Day 60.
Recombinant Zoster Vaccine (CHO cell)
It is used for vaccination of positive control group B subjects in phase Ⅱ clinical trial
Recombinant Zoster Vaccine (CHO cell)
The dosage for each administration is 0.5 mL, containing 50 μg of gE and the AS01B adjuvant system \[QS-21 (50 μg), MPL (50 μg), DOPC (1 mg), and cholesterol (0.25 mg)\], administered intramuscularly into the deltoid muscle. A total of two doses will be given, with the second dose administered 60 days after the first dose.
Recombinant Zoster Vaccine (CHO cell) (Adjuvant control)
It is used for vaccination of adjuvant control group subjects in phase Ⅰ clinical trial
Recombinant Zoster Vaccine (CHO cell) (Adjuvant control)
The dosage for each administration is 0.5 mL, containing 0.25 mL of MF59 and 100 μg of CpG1018, administered intramuscularly into the deltoid muscle. A total of two doses will be given, with the second dose administered 30 days after the first dose.
normal saline
Used in phase Ⅰ clinical trial; To maintain blinding, positive control group A1 and positive control group A2 received placebo on day 0 (for phase II clinical trial).
Normal Saline
The dosage for each administration is 0.5 mL, containing 0.5 mL of NaCl solution, administered intramuscularly into the deltoid muscle. A total of two doses will be given, with the second dose administered 30 days after the first dose (applicable to Phase I clinical trial).
To maintain blinding, subjects in the positive control A1 and positive control A2 groups will receive a placebo on Day 0 (applicable to Phase II clinical trial).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Recombinant zoster vaccine(CHO cell)(low adjuvant)
The dosage for each administration is 0.5 mL, containing 50 μg of gE, 0.25 mL of MF59, and 50 μg of CpG1018, administered intramuscularly into the deltoid muscle. A total of two doses will be given, with the second dose administered 30 days after the first dose.
Recombinant Zoster Vaccine (CHO cell)
The dosage for each administration is 0.5 mL, containing 50 μg of gE, 0.25 mL of MF59, and 100 μg of CpG1018, administered intramuscularly into the deltoid muscle.
Vaccination Schedule 1: A total of two doses will be given, with the second dose administered 30 days after the first dose.
Vaccination Schedule 2: A total of two doses will be given, with the second dose administered 60 days after the first dose \[only applicable to the Phase II Experimental Vaccine Group B2\].
Zoster Vaccine, Live
The dosage for each administration is 0.5 mL, containing not less than 4.3 lg PFU of varicella-zoster live virus, administered subcutaneously at the attachment site of the lower edge of the deltoid muscle on the outer side of the upper arm.
A total of one dose will be given. To maintain blinding, the positive control group A1 will receive a placebo on Day 0 and the Zoster Vaccine, Live on Day 30. The positive control group A2 will receive a placebo on Day 0 and the Zoster Vaccine, Live on Day 60.
Recombinant Zoster Vaccine (CHO cell)
The dosage for each administration is 0.5 mL, containing 50 μg of gE and the AS01B adjuvant system \[QS-21 (50 μg), MPL (50 μg), DOPC (1 mg), and cholesterol (0.25 mg)\], administered intramuscularly into the deltoid muscle. A total of two doses will be given, with the second dose administered 60 days after the first dose.
Recombinant Zoster Vaccine (CHO cell) (Adjuvant control)
The dosage for each administration is 0.5 mL, containing 0.25 mL of MF59 and 100 μg of CpG1018, administered intramuscularly into the deltoid muscle. A total of two doses will be given, with the second dose administered 30 days after the first dose.
Normal Saline
The dosage for each administration is 0.5 mL, containing 0.5 mL of NaCl solution, administered intramuscularly into the deltoid muscle. A total of two doses will be given, with the second dose administered 30 days after the first dose (applicable to Phase I clinical trial).
To maintain blinding, subjects in the positive control A1 and positive control A2 groups will receive a placebo on Day 0 (applicable to Phase II clinical trial).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Voluntarily agrees to participate in the trial, fully understands, and signs the informed consent form.
* Able to attend all scheduled follow-ups and comply with the clinical trial protocol requirements to complete the trial.
* Female participants must meet the following criteria:1)Surgically sterilized or postmenopausal for ≥2 years, or women of childbearing potential (not menopausal or menopausal \<2 years) with a negative pregnancy test and willing to use effective physical contraception (e.g., condoms, intrauterine device) from enrollment until 6 months after full immunization. 2)Agree not to breastfeed from enrollment until 6 months after full immunization.
* Axillary temperature ≤37.0°C.
Exclusion Criteria
* A history of varicella or herpes zoster vaccination.
* Close contact with a varicella/herpes zoster patient within the past year.
* Received immunoglobulin and/or any blood products within 3 months before vaccination.
* Received immunosuppressive treatment within 3 months prior to vaccination (e.g., systemic corticosteroids for ≥14 days, at a dose ≥2 mg/kg/day or ≥20 mg/day of prednisone, or an equivalent dose of prednisone) (excluding inhaled, intra-articular, and topical steroids).
* A history of severe allergic reactions to any vaccine or medication (e.g., anaphylactic shock, allergic laryngeal edema, allergic purpura, thrombocytopenic purpura, local allergic necrosis reactions, severe urticaria, etc.), or a family history of severe allergies.
* Immunocompromised or diagnosed with congenital or acquired immune deficiency diseases, or infected with Human Immunodeficiency Virus (HIV).
* A history of seizures, epilepsy, encephalopathy (such as congenital brain malformation, brain trauma, brain tumors, cerebral hemorrhage, cerebral infarction \[except for infarction without sequelae or lacunar infarction\], brain infections, or brain damage caused by chemical drug poisoning), or psychiatric disorders, or a family history of psychiatric disorders; or other serious neurological diseases.
* Inadequate time interval between vaccination and other vaccines (e.g., inactivated or recombinant subunit vaccines within 14 days prior to vaccination, live attenuated vaccines, viral vector vaccines, or mRNA vaccines within 28 days prior to vaccination).
* Acute illness or an acute exacerbation of a chronic disease within 3 days prior to vaccination, or use of antipyretic, analgesic, or antihistamine medications within 3 days prior to vaccination.
* Suffering from severe infectious skin diseases.
* Ongoing or long-term alcohol and/or drug abuse history (Note: for the past three months, males drinking more than 14 standard drinks per week, females more than 7 standard drinks per week. One standard drink contains 14g of alcohol, equivalent to 360mL of beer, 45mL of liquor at 40% alcohol, or 150mL of wine. Drug abuse refers to the repeated or excessive use of drugs with dependence potential unrelated to recognized medical needs, for non-medical purposes).
* A history of thrombocytopenia or other coagulation disorders that may contraindicate intramuscular injection.
* Severe liver or kidney disease, complications from diabetes, severe cardiovascular diseases, or uncontrolled hypertension despite medication.
* Asplenia or functional asplenia, or any condition leading to splenectomy.
* Abnormal laboratory test results before the first dose, deemed clinically significant by the investigator (only applicable to Phase I).
* Currently participating in other experimental or unregistered clinical trials for products (drugs, vaccines, or devices), or planning to participate in another clinical trial before the end of this trial.
* A history of hematologic or lymphatic system diseases, such as unexplained lymphadenopathy or hematolymphatic lymphoma.
* A history of diagnosed potential immune-mediated diseases, autoimmune diseases, or Guillain-Barré syndrome.
* Any other condition deemed by the investigator to be unsuitable for participation in this clinical trial.
* Positive urine pregnancy test.
* Grade 4 adverse events related to vaccination.
* Severe allergic reactions occurring after vaccination.
* Other situations assessed by the investigator as requiring termination of vaccination.
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yither Biotechnology Co., Ltd
UNKNOWN
Ab&B Bio-tech Co., Ltd.JS
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zhiqiang Xie, Master
Role: PRINCIPAL_INVESTIGATOR
Henan Center for Disease Control and Prevention
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Xiangcheng County Center for Disease Control and Prevention
Xuchang, Henan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Zhiqiang Xie, Master
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VZV-ZHSW-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.